Breast Cancer Clinical Trial
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
Summary
This pilot clinical trial studies how well fraction carbon dioxide (CO2) laser therapy works in treating vaginal atrophy in patients with breast cancer. Fraction CO2 laser therapy uses intense beams of light to cut, burn, or destroy tissue and may remodel vaginal tissue and direct controlled thermal damage of vaginal mucosa.
Full Description
PRIMARY OBJECTIVES:
I. To demonstrate the feasibility of fractionated CO2 laser treatments in patients with breast cancer with vaginal atrophy by determining treatment completion rates and tolerability of treatment.
II. To demonstrate the efficacy of fractionated CO2 laser treatments in patients with breast cancer with vaginal atrophy as determined by improvement from baseline to post treatment in the score of the Vaginal Assessment Scale (VAS).
SECONDARY OBJECTIVES:
I. Sexual behavior/function as measured by the Sexual Experiences Scare, Global sexual satisfaction scale, Female Sexual Function Index (FSFI), and the Female Sexual Distress Scare (FSDS).
II. Other symptoms of urogenital atrophy using the Urogenital Distress Inventory (UDI).
III. Overall patient assessment of symptoms by Patient Global Impression of Improvement scale (PGI-I).
OUTLINE:
Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
After completion of study treatment, patients are followed up at 4 weeks.
Eligibility Criteria
Inclusion Criteria:
Women with non-metastatic breast cancer with any hormone receptor and Her 2 neu status who have completed surgery, chemotherapy, and radiation and are currently on endocrine therapy, single agent Herceptin, or observation
Symptoms of urogenital atrophy including dyspareunia or vaginal dryness
Exclusion Criteria:
Patients with metastatic breast cancer
Vaginal stenosis which would not allow vaginal probe to be placed (based on physician exam)
Active genital infection at the time of enrollment (if present initially, can be treated and then patient can be re-evaluated for eligibility)
Pelvic organ prolapse greater than stage II
Prior reconstructive pelvic surgery involving mesh
Hormone replacement therapy, vaginal estrogen therapy, DHEA, or biosynthetics within 6 weeks prior to enrollment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Columbus Ohio, 43210, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.